Haleon (HLN) Income from Discontinued Operations (2021 - 2023)
Haleon (HLN) posted Income from Discontinued Operations of 436885463.66 for Q4 2023, down 238.96% on a QoQ basis from 128890404.76 in Q2 2023, and up 17.23% year-over-year from 372680227.2 in Q4 2022.
Haleon (HLN) Income from Discontinued Operations (2021 - 2023) Analysis & Trends
Haleon's Income from Discontinued Operations history runs 3 years deep, the most recent figure standing at 436885463.66 for Q4 2023.
- Quarterly Income from Discontinued Operations rose 17.23% year-over-year to 436885463.66 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 1248886395.97 (changed N/A YoY) and the FY2024 annual result came in at 556049787.56, up 13.53% from the prior year.
- Income from Discontinued Operations was 436885463.66 for Q4 2023 at Haleon, down from 128890404.76 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 128890404.76 in Q2 2023 and bottomed at 527817744.51 in Q4 2022.
- A 3-year average of 350428736.88 and a median of 415449935.95 in 2022 frame the typical range for Income from Discontinued Operations.
- Annual changes were most pronounced in 2022 — Income from Discontinued Operations fell 14.82% — and 2023, when it gained 17.23%.
- Haleon's Income from Discontinued Operations stood at 459671617.05 in 2021, then fell by 14.82% to 527817744.51 in 2022, then rose by 17.23% to 436885463.66 in 2023.
- Business Quant data shows HLN's Income from Discontinued Operations at 436885463.66 in Q4 2023, 128890404.76 in Q2 2023, and 155292783.04 in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -436.89 Mn |
| Jun 30, 2023 | -128.89 Mn |
| May 3, 2023 | -155.29 Mn |
| Dec 31, 2022 | -527.82 Mn |
| Sep 20, 2022 | -394.01 Mn |
| Dec 31, 2021 | -459.67 Mn |